Universal Health Services (UHS) Reports Q3 2026 Earnings Amid Mo

Universal Health Services (UHS) reported Q3 2026 earnings with adjusted EPS down 8% YoY to $5.22 and adjusted EBITDA declining to $625M. The company maintained its outlook but warned of potential lower-end results. UHS is trading at a 27.2% discount to its GF Value™ of $240.66, with a GF Score™ of 91, indicating strong fundamentals. GuruFocus highlights UHS's undervaluation and growth potential, while insider activity shows no purchases and $1.2M in sales.

Original reporting
Published Oct 28, 2026, 5:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 6:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$UHS
Bearish
high confidence
Mentioned
$UHS
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$UHSBearishMed
01

Why it matters

The earnings decline may trigger short‑term selling, but the sizable valuation discount could attract value‑oriented investors.

02

Market read

UHS earnings miss is the primary market‑moving event; the article provides the first public disclosure of the Q3 numbers.

03

What to watch

Strong demand trends in acute care and behavioral health could support future earnings recovery.

Relevance 7/10Novelty 7/10Timing: after-market release on Oct 28

Background

Universal Health Services is a $10.3B U.S.-based provider of inpatient psychiatric and acute care hospitals.

Company-level read

Ticker impact

$UHSBearishHigh confidence
Context

UHS reported Q3 2026 adjusted EPS of $5.22, an 8% YoY decline, and EBITDA of $625M, both down from the prior year.

Expected impact

likely downward pressure as investors price in weaker earnings

Evidence & confidence

The decline in EPS and EBITDA signals slower growth, and the guidance remains unchanged, which may not satisfy the market.

Market effects

Healthcare services sector may see modest pullback as a large peer shows earnings weakness.

U.S. hospital operators could face heightened scrutiny on margins.

Limited to U.S. healthcare investors; no broader macro effect.

Counterpoint

Valuation metrics suggest the stock is still 27% below intrinsic value, offering a buying opportunity despite the earnings miss.

Key entities

  • Universal Health Services

    Operator of behavioral health and acute care facilities.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$CNCMed

Health insurers, hospitals rally after sweeping midterm win for Democrats

Shares of Medicaid-focused health insurers (Centene, Elevance, Molina) and hospital operators (HCA, Tenet, Universal) rose after Democrats won the midterms, raising hopes for sector-friendly policies. Analysts expect delays in Trump's OBBBA, easing pressure on Medicaid and ACA insurers, and potential extensions of enhanced subsidies. Year-to-date gains vary among companies.

$UHSHighAI 8/10

Softer surgery volumes, hospital woes dampened UHS’ Q3 earnings

Universal Health Services (UHS) lowered its 2026 earnings expectations due to declining surgeries and struggles at some hospitals. Q3 net income fell 17% to $308M, while revenues rose 5% to $4.7B. Challenges include lower surgery volumes, delays in new hospital profitability, and rising uninsured patients. UHS expects to be at the lower end of its guidance range for 2024.

$UHSMed

Guggenheim cuts Universal Health Services stock price target to $201 on weak Q3

Guggenheim reduced its price target for Universal Health Services (UHS) to $201 from $209, citing weak Q3 2026 EBITDA and macro pressures. UHS stock is down 8.5% in a week. The company lowered its 2026 EBITDA guidance but sees potential upside from expansions. UHS reported Q3 EPS of $5.22 and revenue of $4.73B, slightly beating estimates. Raymond James kept a Market Perform rating, noting softer profit trends and a cautious 2027 outlook.